PMID- 25556085
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20220316
IS  - 1179-1942 (Electronic)
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 38
IP  - 2
DP  - 2015 Feb
TI  - Consensus recommendations for systematic evaluation of drug-drug interaction 
      evidence for clinical decision support.
PG  - 197-206
LID - 10.1007/s40264-014-0262-8 [doi]
AB  - BACKGROUND: Healthcare organizations, compendia, and drug knowledgebase vendors 
      use varying methods to evaluate and synthesize evidence on drug-drug interactions 
      (DDIs). This situation has a negative effect on electronic prescribing and 
      medication information systems that warn clinicians of potentially harmful 
      medication combinations. OBJECTIVE: The aim of this study was to provide 
      recommendations for systematic evaluation of evidence for DDIs from the 
      scientific literature, drug product labeling, and regulatory documents. METHODS: 
      A conference series was conducted to develop a structured process to improve the 
      quality of DDI alerting systems. Three expert workgroups were assembled to 
      address the goals of the conference. The Evidence Workgroup consisted of 18 
      individuals with expertise in pharmacology, drug information, biomedical 
      informatics, and clinical decision support. Workgroup members met via webinar 12 
      times from January 2013 to February 2014. Two in-person meetings were conducted 
      in May and September 2013 to reach consensus on recommendations. RESULTS: We 
      developed expert consensus answers to the following three key questions. (i) What 
      is the best approach to evaluate DDI evidence? (ii) What evidence is required for 
      a DDI to be applicable to an entire class of drugs? (iii) How should a structured 
      evaluation process be vetted and validated? CONCLUSION: Evidence-based decision 
      support for DDIs requires consistent application of transparent and systematic 
      methods to evaluate the evidence. Drug compendia and clinical decision support 
      systems in which these recommendations are implemented should be able to provide 
      higher-quality information about DDIs.
FAU - Scheife, Richard T
AU  - Scheife RT
AD  - Tufts University School of Medicine, Boston, MA, USA.
FAU - Hines, Lisa E
AU  - Hines LE
FAU - Boyce, Richard D
AU  - Boyce RD
FAU - Chung, Sophie P
AU  - Chung SP
FAU - Momper, Jeremiah D
AU  - Momper JD
FAU - Sommer, Christine D
AU  - Sommer CD
FAU - Abernethy, Darrell R
AU  - Abernethy DR
FAU - Horn, John R
AU  - Horn JR
FAU - Sklar, Stephen J
AU  - Sklar SJ
FAU - Wong, Samantha K
AU  - Wong SK
FAU - Jones, Gretchen
AU  - Jones G
FAU - Brown, Mary L
AU  - Brown ML
FAU - Grizzle, Amy J
AU  - Grizzle AJ
FAU - Comes, Susan
AU  - Comes S
FAU - Wilkins, Tricia Lee
AU  - Wilkins TL
FAU - Borst, Clarissa
AU  - Borst C
FAU - Wittie, Michael A
AU  - Wittie MA
FAU - Malone, Daniel C
AU  - Malone DC
LA  - eng
GR  - R01 LM011838-01/LM/NLM NIH HHS/United States
GR  - R01 LM011838/LM/NLM NIH HHS/United States
GR  - R13 HS021826/HS/AHRQ HHS/United States
GR  - K01 AG044433-01/AG/NIA NIH HHS/United States
GR  - K12 HS019461-01/HS/AHRQ HHS/United States
GR  - K12 HS019461/HS/AHRQ HHS/United States
GR  - 1R13HS021826-01/HS/AHRQ HHS/United States
GR  - K01 AG044433/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
SB  - IM
MH  - Adverse Drug Reaction Reporting Systems/*standards
MH  - Databases, Factual
MH  - Decision Support Systems, Clinical/*standards
MH  - *Drug Interactions
MH  - Drug Labeling
MH  - *Electronic Prescribing
MH  - Evidence-Based Medicine/*standards
MH  - Practice Guidelines as Topic
PMC - PMC4624322
MID - NIHMS732017
EDAT- 2015/01/04 06:00
MHDA- 2015/10/27 06:00
PMCR- 2016/02/01
CRDT- 2015/01/04 06:00
PHST- 2015/01/04 06:00 [entrez]
PHST- 2015/01/04 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 10.1007/s40264-014-0262-8 [doi]
PST - ppublish
SO  - Drug Saf. 2015 Feb;38(2):197-206. doi: 10.1007/s40264-014-0262-8.